Evidence map›Paper›PMID 34066482›Full record

ReviewInternational journal of molecular sciences2021

Reviewing the Significance of Vitamin D Substitution in Monoclonal Gammopathies.

Vanessa Innao, Alessandro Allegra, Lia Ginaldi, Giovanni Pioggia, Massimo De Martinis, Caterina Musolino, Sebastiano Gangemi

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06987708 (Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers Associated With Monoclonal Gammopathy of Unknown Significance), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06987708 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers Associated With Monoclonal Gammopathy of Unknown Significance (MGUS) and Smoldering Myeloma (SM): A Prospective Intervention Pilot Study

TypeinterventionalSponsorHackensack Meridian HealthRan2026 to 2028Enrolled67ConditionsMonoclonal Gammopathy of Uncertain Significance, Smoldering MyelomaArmsThe Multimodal Lifestyle Intervention
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Risk factors for multiple myeloma and its precursor diseases.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Review
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Vanessa InnaoDepartment of Human Pathology in Adulthood and Childhood "Gaetano Barresi", Division of Haematology, University of Messina, 98125 Messina, Italy.ORCID 0000-0001-7596-1912
Alessandro AllegraDepartment of Human Pathology in Adulthood and Childhood "Gaetano Barresi", Division of Haematology, University of Messina, 98125 Messina, Italy.ORCID 0000-0001-6156-8239
Lia GinaldiDepartment of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Giovanni PioggiaInstitute for Biomedical Research and Innovation (IRIB), National Research Council of Italy (CNR), 98164 Messina, Italy.ORCID 0000-0002-8089-7449
Massimo De MartinisDepartment of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.ORCID 0000-0003-4253-1312
Caterina MusolinoDepartment of Human Pathology in Adulthood and Childhood "Gaetano Barresi", Division of Haematology, University of Messina, 98125 Messina, Italy.
Sebastiano GangemiDepartment of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, University of Messina, 98125 Messina, Italy.
University of Messina · ITUniversity of Teramo · ITInstitute for Biomedical Research and Innovation · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitamin D is a steroid hormone that is essential for bone mineral metabolism and it has several other effects in the body, including anti-cancer actions. Vitamin D causes a reduction in cell growth by interrupting the cell cycle. Moreover, the active form of vitamin D, i.e., 1,25-dihydroxyvitamin D, exerts various effects via its interaction with the vitamin D receptor on the innate and adaptive immune system, which could be relevant in the onset of tumors. Multiple myeloma is a treatable but incurable malignancy characterized by the growth of clonal plasma cells in protective niches in the bone marrow. In patients affected by multiple myeloma, vitamin D deficiency is commonly correlated with an advanced stage of the disease, greater risk of progression, the development of pathological fractures, and a worse prognosis. Changes in the vitamin D receptor often contribute to the occurrence and progress of deficiencies, which can be overcome by supplementation with vitamin D or analogues. However, in spite of the findings available in the literature, there is no clear standard of care and clinical practice varies. Further research is needed to better understand how vitamin D influences outcomes in patients with monoclonal gammopathies.

Indexed as

AnimalsDisease ProgressionHumansImmune SystemModels, BiologicalParaproteinemiasRisk FactorsVitamin DVitamin Danti-myeloma therapycancerimmune responseMGUSmultiple myelomasmoldering multiple myelomavitamin D

Identifiers

PMID34066482
PMCPMC8124934
OpenAlexW3158802529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.